Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Operating Expenses (2019 - 2025)

Cyclerion Therapeutics has reported Operating Expenses over the past 7 years, most recently at $1.9 million for Q3 2025.

  • Quarterly results put Operating Expenses at $1.9 million for Q3 2025, up 42.28% from a year ago — trailing twelve months through Sep 2025 was $6.5 million (up 6.03% YoY), and the annual figure for FY2024 was $5.6 million, down 56.54%.
  • Operating Expenses for Q3 2025 was $1.9 million at Cyclerion Therapeutics, up from $1.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for CYCN hit a ceiling of $19.2 million in Q2 2021 and a floor of $1.3 million in Q4 2024.
  • Median Operating Expenses over the past 5 years was $3.3 million (2023), compared with a mean of $6.3 million.
  • Biggest five-year swings in Operating Expenses: tumbled 86.43% in 2023 and later skyrocketed 42.28% in 2025.
  • Cyclerion Therapeutics' Operating Expenses stood at $14.9 million in 2021, then crashed by 70.04% to $4.5 million in 2022, then crashed by 59.71% to $1.8 million in 2023, then dropped by 27.35% to $1.3 million in 2024, then skyrocketed by 44.25% to $1.9 million in 2025.
  • The last three reported values for Operating Expenses were $1.9 million (Q3 2025), $1.8 million (Q2 2025), and $1.5 million (Q1 2025) per Business Quant data.